(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients...
Stats | |
---|---|
今日成交量 | 641 108 |
平均成交量 | 1.22M |
市值 | 7.88M |
EPS | $-0.780 ( 2024-04-26 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.150 |
ATR14 | $0.00600 (1.43%) |
音量 相关性
ASLAN Pharmaceuticals 相关性 - 货币/商品
ASLAN Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $12.00M |
毛利润: | $11.65M (97.10 %) |
EPS: | $-2.69 |
FY | 2023 |
营收: | $12.00M |
毛利润: | $11.65M (97.10 %) |
EPS: | $-2.69 |
FY | 2022 |
营收: | $0 |
毛利润: | $-331 752 (0.00 %) |
EPS: | $-3.68 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.815 |
Financial Reports:
No articles found.
ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。